ENTA

ENTA

USD

Enanta Pharmaceuticals Inc. Common Stock

$7.950+0.385 (5.089%)

السعر في الوقت الحقيقي

Healthcare
التكنولوجيا الحيوية
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$7.565

الأعلى

$8.470

الأدنى

$7.475

الحجم

0.24M

أساسيات الشركة

القيمة السوقية

169.9M

الصناعة

التكنولوجيا الحيوية

البلد

United States

إحصاءات التداول

متوسط الحجم

0.20M

البورصة

NMS

العملة

USD

نطاق 52 أسبوعاً

الأدنى $4.09الحالي $7.950الأعلى $17.235

أخبار ذات صلة

BusinessWire

Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

MAVYRET® (glecaprevir/pibrentasvir) is Now the Only Direct Acting Antiviral Therapy Approved to Treat Patients with Acute Hepatitis C Virus (HCV) in Eight Weeks with a 96% Cure Rate1*† FDA Approval Now

عرض المزيد
Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus
Analyst Upgrades

JMP Securities Maintains Market Outperform on Enanta Pharma, Raises Price Target to $24

JMP Securities analyst Roy Buchanan maintains Enanta Pharma with a Market Outperform and raises the price target from $23 to $24.

عرض المزيد
JMP Securities Maintains Market Outperform on Enanta Pharma, Raises Price Target to $24
BusinessWire

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D.,

عرض المزيد
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
BusinessWire

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company's

عرض المزيد
Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.